Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Shisong is an Oxford University researcher in the Department of Oncology, and the CTO of Oxford Vacmedix, which has developed a technique to grow overlapping peptides in bacteria, to use for cellular immunity vaccines.

Oxford Vacmedix has raised almost £1 million in funding, and is now looking to raise a second round of around £10 million.  There are two centers, one in Oxford and one in China, working on this technology.

Q: What is your background?  Why are you doing this?
A: I studied medicine in China, and then came to London and Harvard for my PhD and initial post doc post.  I had been involved in immunology in London and the US, and was working on HIV and peptide segments for vaccines when I came to Oxford.  I started looking into ways of producing these overlapping peptide segments, and starting using bacteria as a cheap method.

Read more (Enterprising Oxford website)